North America Anatomic Pathology Market

Market Introduction

The anatomic pathology is a significant part of the study and treatment of the diseases. Anatomic pathology is a broad field that includes decedent pathology, surgical pathology, cytopathology, neuropathology, and ophthalmic pathology. The anatomic pathology is usually performed in the medical laboratories of hospitals and diagnostics laboratories.

North America Anatomic Pathology Strategic Insights

Strategic insights for the North America Anatomic Pathology provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Anatomic Pathology Report Scope

North America Anatomic Pathology Regional Insights

The geographic scope of the North America Anatomic Pathology refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The North America anatomic pathology market is expected to reach US$ 13,970.95 million by 2028 from US$ 8,870.41 million in 2021; it is estimated to grow at a CAGR of 6.7% from 2021 to 2028. The growth of the market is attributed to key driving factors such as the increasing prevalence of cancer and other diseases and the growing focus on personalized medicines. However, the lack of skilled professionals and the implementation of stringent government regulations hinder the market growth.

Cancer has a major impact on society across the world. The burden of cancer on healthcare systems is significantly increasing worldwide as it is among the leading causes of death. According to the National Cancer Institute, in 2018, there were 18.1 million new cases and 9.5 million people died from the disease worldwide. ~30% of all premature deaths from noncommunicable diseases among adults aged 30–69 are caused because of cancer. Lung cancer is the most frequently diagnosed cancer in the world. The prevalence of diabetes is growing, especially in the world’s middle-income countries, due to increase in overweight, obesity, and unhealthy diet. Overweight and obesity are among the prime most risk factors causing Type 2 diabetes. According to the IDF Diabetes Atlas Ninth Edition, in 2019, ~463 million adults, from the age range 20–79 years, were living with diabetes; and this number would rise to 700 million. Owing to the increasing prevalence of cancer and other diseases, government agencies, healthcare providers, and institutions are being compelled to contribute toward disease diagnosis and treatment initiatives. Thus, a surge in the prevalence of cancer and other targeted diseases is driving the North America anatomic pathology market growth. Personalized medicines are used in the treatment of diseases such as breast cancer and cardiovascular diseases. The personalized anticancer medicines exhibit fewer and less severe side effects than other types of treatment as they are designed for specific actions. Further, with the ongoing progress in research and clinical studies, personalized medicines are likely to reach even great potential to improve the quality of patient care. Thus, the growing focus on personalized medicines is boosting the anatomic pathology market growth.

The COVID-19 pandemic and the redirection in healthcare resources have impacted every aspect of the diagnostics industry, including the anatomic pathology market. The closure of clinics, operation rooms, and physician offices, and the “stay-at-home” mandates across North America severely impacted the acquisition and submission of specimens for pathology evaluation. In the last two years, the number of patient visits to hospitals has reduced significantly, despite emergency and OPD services being available in hospitals. Further, as most hospitals invested their efforts and resources in diagnosing and treating COVID-19, many planned surgeries were canceled or delayed. As a result, various early cancer detection systems were deactivated, and all autopsies were suspended. According to the World Economic Forum, 28 million elective surgeries and 38% of global cancer surgeries have been delayed. Thus, the number of surgical pathology and cytology samples received in anatomic pathology labs reduced significantly. As a result, the number of diagnostic tests has reduced. The reduction has further reduced the sales of anatomic pathology products during the Q2 of 2020. Moreover, due to the robust increase in COVID- 19 patients, pathology laboratories are now prioritizing and focusing on COVID-19 tests. The rapid increase in the number of infected patients in the US and Canada is likely to hamper the growth of the North America anatomy pathology market in the future. Currently, many countries are relaxing the lockdown restrictions, and most hospitals have resumed elective surgeries. As a result, the number of diagnostic tests is now increasing. However, due to the effects of the COVID-19 pandemic, the overall growth rate of the anatomic pathology market is less than the previous year.

Key Market Segments

Based on product and service, the North America anatomic pathology market is segmented into instruments, consumables, and services. The services segment held the largest share of the market in 2021, whereas the instruments segment is anticipated to register the highest CAGR of the market during the forecast period.

By application, the North America anatomic pathology market is segmented into disease diagnosis, drug discovery and development, and others. The disease diagnosis segment held the largest market share in 2021. However, the drug discovery and development segment is anticipated to register the highest CAGR of the market during 2021–2028.

The North America anatomic pathology market, based on end user, is segmented into hospitals, research laboratories, diagnostic laboratories, and others. The others segment consists of pharmaceutical and biotechnology companies and contract research organizations (CROs). The hospitals segment held the largest share of the market in 2021, and the diagnostic laboratories segment is anticipated to register the highest CAGR of the market during the forecast period.

Major Sources and Companies Listed

A few of the primary and secondary sources  referred to while preparing the report on the North America anatomic pathology market are the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and College of American Pathologists (CAP).

Reasons to buy the report

• Determine prospective investment areas based on a detailed trend analysis of North America anatomic pathology market over the next years.
• Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
• Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
• Identify the major channels driving the North America anatomic pathology market, providing a clear picture of future opportunities that will help analyze, resulting in revenue expansion.
• Channelize resources by focusing on the ongoing programs undertaken by the different countries within the North America anatomic pathology market.

NORTH AMERICA ANATOMIC PATHOLOGY MARKET SEGMENTATION

By

Product

s and Services

• Services
• Consumables
• Instruments

By

Application

• Disease Diagnosis
• Drug Discovery and Development
• Others

By End User

• Hospitals
• Research Laboratories
• Diagnostic Laboratories
• Others

By Country

• US
• Canada
• Mexico

Company Profiles

• F. HOFFMANN-LA ROCHE LTD.
• Danaher
• Hologic, Inc.
• Agilent Technologies, Inc.
• BioGenex
• Diapath S.p.A.
• Bio SB
• MERCK KGaA
• BD
• PHC Holdings Corporation